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ABSTRACT 
Poorly controlled diabetes mellitus can result in serious complications. Gene therapy is 
increasingly being considered as an alternative approach to treat diabetes, because of its 
ability to induce physiological insulin secretion and it allows patients to escape insulin 
injections. The properties of gut K and L-cells, including glucose sensitivity, the ability to 
process insulin and a regulated secretion pathway support their use as surrogate β-cells. 
Previous in vitro studies have provided sufficient evidence supporting the use of these cells 
for gene therapy studies. Therefore, we examined the ability of K and L-cells to produce 
insulin in diabetic mice. Chitosan nanoparticles were used to transfer the insulin gene into 
intestinal cells via oral administration. The efficiency of chitosan as a gene vehicle was 
investigated through the use of reporter gene. Insulin mRNA and protein expression levels 
were measured by RT-PCR and ELISA, respectively. Blood glucose testing revealed that this 
treatment reduced glucose levels in diabetic mice. The decrease in blood glucose level in the 
first week of treatment was greater in mice with K-cell specific insulin expression compared 
with mice with L-cellspecific insulin expression. These results indicate that inducing insulin 
secretion in K-cells conferred a quicker response to gene therapy. 
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